KLRC1 and neoplasm: An anti-NKG2A monoclonal antibody that binds NKG2A, the inhibitory receptor present on both NK cells and CD8+ T cells, promoted anti-tumor immunity of these immune cell subsets and thus, anti-NKG2A might have better therapeutic efficacy since it targets both NK cells and CD8+ T cells [90,91].